Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating today.

Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising clinical data from Cabaletta Bio’s RESET trial. The trial results showed that a significant number of patients with various autoimmune conditions, such as myositis, systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), achieved clinical responses after being treated with rese-cel (CABA-201). Notably, in the myositis group, seven out of eight patients responded positively, with some achieving major improvements while off immunomodulators.
Additionally, the rese-cel treatment demonstrated effectiveness in SLE and SSc patients, with all non-renal SLE patients reaching remission and SSc patients showing substantial improvements in skin scores. These encouraging outcomes, particularly the ability to maintain responses without ongoing immunosuppression, underscore the potential of rese-cel as a transformative therapy. This strong clinical performance supports the Buy rating, as it suggests a positive outlook for Cabaletta Bio’s future developments and market potential.

According to TipRanks, Corwin is a 3-star analyst with an average return of 3.4% and a 43.46% success rate. Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Allogene Therapeutics, and BioMarin Pharmaceutical.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.